image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 2.05
-10.4 %
$ 71.2 M
Market Cap
-3.05
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one MBOT stock under the worst case scenario is HIDDEN Compared to the current market price of 2.05 USD, Microbot Medical Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one MBOT stock under the base case scenario is HIDDEN Compared to the current market price of 2.05 USD, Microbot Medical Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one MBOT stock under the best case scenario is HIDDEN Compared to the current market price of 2.05 USD, Microbot Medical Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart MBOT

image
$3.0$3.0$2.8$2.8$2.6$2.6$2.4$2.4$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.8Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
0 REVENUE
0.00%
0 OPERATING INCOME
100.00%
-11.4 M NET INCOME
-6.55%
-8.83 M OPERATING CASH FLOW
-3.45%
1.54 M INVESTING CASH FLOW
-22.10%
7.94 M FINANCING CASH FLOW
21.01%
0 REVENUE
0.00%
-3.43 M OPERATING INCOME
-3.94%
-3.39 M NET INCOME
-5.51%
-1.69 M OPERATING CASH FLOW
38.71%
1.5 M INVESTING CASH FLOW
967.86%
2.83 M FINANCING CASH FLOW
347.39%
Balance Sheet Microbot Medical Inc.
image
Current Assets 5.82 M
Cash & Short-Term Investments 5.47 M
Receivables 300 K
Other Current Assets 49 K
Non-Current Assets 212 K
Long-Term Investments 0
PP&E 212 K
Other Non-Current Assets 0
90.70 %4.97 %3.52 %Total Assets$6.0m
Current Liabilities 2.46 M
Accounts Payable 165 K
Short-Term Debt 0
Other Current Liabilities 2.3 M
Non-Current Liabilities 111 K
Long-Term Debt 111 K
Other Non-Current Liabilities 0
6.42 %89.26 %4.32 %Total Liabilities$2.6m
EFFICIENCY
Earnings Waterfall Microbot Medical Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 11.6 M
Operating Income 0
Other Expenses 11.4 M
Net Income -11.4 M
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)000(12m)0(11m)(11m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
5.16% ROE
5.16%
3.02% ROA
3.02%
0.00% ROIC
0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Microbot Medical Inc.
image
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -11.4 M
Depreciation & Amortization 91 K
Capital Expenditures -25 K
Stock-Based Compensation 1.35 M
Change in Working Capital 942 K
Others 1.18 M
Free Cash Flow -8.85 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Microbot Medical Inc.
image
MBOT has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Microbot Medical Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Microbot Medical® Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System Successful robotic navigation was achieved in every case and  met the primary endpoint of the study LIBERTY ® showed a 92% reduction in radiation exposure with no adverse events reported HINGHAM, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, presented for the first time the data from its ACCESS-PVI pivotal trial at the Society of Interventional Radiology (SIR) annual meeting. globenewswire.com - 3 weeks ago
REMINDER: Microbot Medical Announces Data from the Company's ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Annual Meeting Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second Quarter Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second Quarter globenewswire.com - 1 month ago
Microbot Medical Appoints Seasoned Endovascular Sales Executive to Lead its U.S. Sales Activities for LIBERTY® Endovascular Robotic System Mr. Paul Mullen Most Recently Served as the Director of Sales at Inari Medical which was Acquired by Stryker Corporation Earlier This Year globenewswire.com - 1 month ago
Robotic Telesurgery Data from Collaboration with Corewell Health™ Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting BRAINTREE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced its collaboration with Corewell Health™ has reached another meaningful milestone. globenewswire.com - 2 months ago
Microbot Medical Closes $13 Million Registered Direct Offering BRAINTREE, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 6,103,289 shares of the Company's common stock at a purchase price of $2.13 per share of common stock. In addition, in a concurrent private placement, the Company issued unregistered short-term series I preferred investment options. The short-term series I preferred investment options to purchase up to 12,206,578 shares of common stock have an exercise price of $2.13 per share and will be exercisable for a period of two years beginning on the later of (i) the effective date of the increase of the Company's authorized shares of common stock following stockholder approval and (ii) the effective date of stockholder approval of the issuance of the series I preferred investment options and the shares issuable upon exercise thereof. globenewswire.com - 2 months ago
Microbot Medical Announces $13 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules BRAINTREE, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 6,103,289 shares of the Company's common stock at a purchase price of $2.13 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered short-term series I preferred investment options. The short-term series I preferred investment options to purchase up to 12,206,578 shares of common stock have an exercise price of $2.13 per share and will be exercisable for a period of two years beginning on the later of (i) the effective date of the increase of the Company's authorized shares of common stock following stockholder approval and (ii) the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about February 11, 2025, subject to the satisfaction of customary closing conditions. globenewswire.com - 2 months ago
Microbot Medical Closes $8.6 Million Registered Direct Offering BRAINTREE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 3,788,550 shares of the Company's common stock at a purchase price of $2.27 per share of common stock. In addition, in a concurrent private placement, the Company issued unregistered short-term series H preferred investment options. The short-term series H preferred investment options to purchase up to 7,577,100 shares of common stock have an exercise price of $2.10 per share and are immediately exercisable following issuance for a period of two years thereafter. globenewswire.com - 3 months ago
Microbot Medical Raises a Total of Approximately $11.8 Million in Gross Proceeds from Registered Direct Offering and Previously Announced ATM Facility HINGHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 4,000,001 shares of the Company's common stock at a purchase price of $1.75 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company issued unregistered short-term series G preferred investment options. The short-term series G preferred investment options to purchase up to 8,000,002 shares of common stock have an exercise price of $1.75 per share and are immediately exercisable following issuance for a period of two years thereafter. globenewswire.com - 3 months ago
Microbot Medical® Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY® Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025 Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025 globenewswire.com - 4 months ago
MBOT Stock Gains Following FDA Submission of the LIBERTY System Microbot Medical announces the submission of its LIBERTY System for FDA marketing clearance. zacks.com - 4 months ago
Microbot Medical® CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access Livestream Interview Can be Viewed Today at 10:50am ET at Benzinga All Access Live globenewswire.com - 4 months ago
Microbot Medical Stock Rises After Completing ACCESS-PVI Trial MBOT announces the successful completion of its ACCESS-PVI clinical trial for the LIBERTY Endovascular Robotic Surgical System, paving the way for FDA submission. zacks.com - 6 months ago
8. Profile Summary

Microbot Medical Inc. MBOT

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 71.2 M
Dividend Yield 0.00%
Description Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Contact 25 Recreation Park Drive, Hingham, MA, 02043 https://www.microbotmedical.com
IPO Date March 25, 1992
Employees 20
Officers Mr. Paul Mullen Vice President of Sales Mr. Harel Gadot Co-Founder, President, Chief Executive Officer & Chairman Dr. Juan Diaz-Cartelle Chief Medical Officer Ms. Michal Ahuvia Director of Operations Dr. Simon Sharon MBA, MSc Chief Technology Officer & GM of Microbot Israel Ms. Rachel Vaknin Chief Financial Officer